About cervical cancer


  1. Alliance for Cervical Cancer Prevention (ACCP). The Case for Investing in Cervical Cancer Prevention. Seattle: ACCP, 2004. Cervical Cancer Prevention Issues in Depth. Available at: www.path.org/files/RH_accp_case.pdf
  2. Ferlay J, Bray F, Pisani P, Parkin DM, International Agency for Research on Cancer (IARC). GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. (2.0) Lyon, France: International Agency for Research on Cancer; 2004. Available at: www-dep.iarc.fr/globocan/database.htm.
  3. Gold MA. Currrent cervical cancer screening guidelines and impact of prophylactic HPV vaccines. OBG Management. 2006;(Suppl):S11–S17.
  4. Sankaranarayanan R. Overview of cervical cancer in the developing world. International Journal of Gynaecology and Obstetrics. 2006;95(Suppl 1):S205–S210.
  5. Sherris J, Agurto I, Arrossi S, et al. Advocating for cervical cancer prevention. International Journal of Gynaecology and Obstetrics. 2005;89(Suppl 2):S46–S54.
  6. Spitzer M. Human Papillomavirus: epidemiology, natural history, and clincal sequelae. OBG Management. 2006;(Suppl):S5–S10.
  7. Cox J. Introduction: Reducing the burden of cervical cancer and HPV-related diseases through vaccination. Current Opinion in Obstetrics and Gynecology. 2006;18(Suppl 1):S3–S4.
  8. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. The EMBO Journal. 1984;3(5):1151–1157.
  9. US Centers for Disease Control and Prevention (CDC). Genital HPV infection: CDC Fact Sheet. November 24, 2009. Available at: www.cdc.gov/std/HPV/STDFact-HPV.htm.
  10. Koutsky L. Epidemiology of Genital Human Papillomavirus Infection. American Journal of Medicine. 1997;102(5A):3–8.
  11. Crum CP, Abbott DW, Quade BJ. Cervical cancer screening: from the papanicolaou smear to the vaccine era. Journal of Clinical Oncology. 2003;21(Suppl 10):224–230.
  12. Brown D, Shew M, Qadadri B, et al. A Longitudinal Study of Genital Human Papillomavirus Infection in a Cohort of Closely Followed Adolescent Women. The Journal of Infectious Diseases. 2005;191(2):182–192.
  13. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(Suppl 3):S3/42–S3/51.
  14. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271):1831–1836.
  15. Population Reference Bureau and ACCP. Preventing Cervical Cancer Worldwide. Washington, DC; Seattle, WA: Population Reference Bureau; 2004. Available at:
  16. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24(Suppl 3):S26–S34.
  17. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl. 3):S1–S10.
  18. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. International Journal of Cancer. 2007;121(3):621–632.
  19. Snijders PJF, Steenbergen RDM, Heideman DAM, MEIJER CJLM. HPV-mediated cervical carcinogenesis: concepts and clinical implications. Journal of Pathology. 2006;208(2):152–164.
  20. World Health Organization (WHO). Comprehensive cervical cancer control: a guide to essential practice. Geneva: WHO; 2006.
  21. zur Hausen H. Infections Causing Human Cancer. Weinheim: Wiley-VCH; 2006.
  22. Villa LL. Biology of genital human papillomaviruses. International Journal of Gynecology and Obstetrics. 2006;94(Suppl 1):S3–S7.
  23. National Cancer Institute website. Cervical Cancer Prevention page. Available at: www.cancer.gov/cancertopics/pdq/
    . Accessed December 23, 2009.
  24. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. The New England Journal of Medicine. 2006;354(25):2645–2654.
  25. Dempsey AF, Gebremariam A, Koutsky L, Manhart L. Behavior in early adolescence and risk of human papillomavirus infection as a young adult: results from a population-based study. Pediatrics. 2008;122(1):1–7.
  26. Merck & Co., Inc. Gardasil® package insert. Whitehouse Station, NJ: Merck & Co. Inc; 2009. Available at: www.merck.com/product/home.html#G.
  27. Electronic Medicines Compendium website. Cervarix Summary of Product Characteristics page. Available at:
    emc.medicines.org.uk/medicine/20204/SPC/Cervarix. Accessed December 23, 2009.
  28. Ault KA, FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861–1868.
  29. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314.
  30. Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine. 2009;27(Suppl 1):A46–A53.
  31. Romanowski B, GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374(9706):1975–1985.
  32. Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine. 2009;27(41):5612–5619.
  33. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25(26):4931–4939.
  34. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. Journal of Infectious Diseases. 2009;199(7):919–922.
  35. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. Journal of the American Medical Association. 2009;302(7):750–757.
  36. WHO. WHO Position Paper on HPV Vaccines. Weekly Epidemiological Record. 2009;84(15):117–132. Available at: www.who.int/wer/2009/wer8415/en.
  37. GAVI Alliance website. Which vaccines to invest in and when. GAVI's strategic approach. Available at:
    www.gavialliance.org/vision/strategy/vaccine_investment. Accessed December 23, 2009.
  38. PATH. Shaping a strategy to introduce HPV vaccines in Uganda. Seattle, WA: PATH; 2009.
  39. Tsu VD, Pollack AE. Preventing cervical cancer in low-resource settings: how far have we come and what does the future hold? International Journal of Gynecology & Obstetrics. 2005;89(Suppl 2):S55–S59.
  40. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24(Suppl 3):S171–S177.
  41. Wright TC, Bosch FX, Franco EL, et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine. 2006;24(Suppl 3):S3/251–S3/261.
  42. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. British Medical Journal. 2009;339:b3884.


  43. PATH. Current and future HPV vaccines: promises and challenges. Seattle, WA: PATH; 2006.
  44. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine. 2008;26(Suppl 10):K62–K67.
  45. Hildesheim A, Markowitz L, Avila MH, Franceschi S. Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Vaccine. 2006;24(Suppl 3):S227–S232.
  46. Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opinion on Biological Therapy. 2008;8(4):421–439.
  47. Sherris J, Wittet S, Kleine A, et al. Evidence-based, alternative cervical cancer screening approaches in low-resource settings. International Perspectives on Sexual and Reproductive Health. 2009;35(3):147–154. Available at:
  48. Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine. 2006;24 Suppl 3:S3/63–S3/70.
  49. US Centers for Disease Control and Prevention website. HPV-Associated Cancers and Poverty Levels page. Available at:
    www.cdc.gov/cancer/hpv/statistics/poverty.htm. Accessed December 23, 2009.
  50. Sankaranarayanan R, Bhatla N, Gravitt PE, et al. Human Papillomavirus Infection and Cervical Cancer Prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine. 2008;26(Suppl 12):M43–M52.
  51. Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine. 2006;24(Suppl. 3):S71–S77.
  52. Agurto I, Arrossi S, White S, et al. Involving the community in cervical cancer prevention programs. International Journal of Gynaecology and Obstetrics. 2005;89(Suppl 2):S38–S45.
  53. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26 Suppl 10:K29–K41.
  54. Denny L, Ngan HYS. Section B: Malignant manifestations of HPV infection Carcinoma of the cervix, vulva, vagina, anus, and penis. International Journal of Gynecology & Obstetrics. 2006;94(Suppl 1):S50–S55.
  55. Villa LL, Denny L. Chapter 7: Methods for detection of HPV infection and its clinical utility. International Journal of Gynecology & Obstetrics. 2006;94(Suppl 1):S71–S80.
  56. Arbyn M, Sasieni P, Meijer C, Clavel C, Koliopoulos G, Dillner J. Clinical applications of HPV testing: A summary of meta-analyses. Vaccine. 2006;24:78–89.
  57. US Food and Drug Administration (FDA) website. FDA approved first DNA test for two types of human papillomavirus [press release]. Silver Spring, MD: FDA; March 13, 2009. Available at:
  58. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. International Journal of Gynaecology and Obstetrics. 2005;89 Suppl 2:S4–S12.
  59. Sellors J. HPV in screening and triage: towards an affordable test. HPV Today. 2009;8:4–5.
  60. Castro W, Gage J, Gaffikin L, et al. Effectiveness, Safety, and Acceptability of Cryotherapy: A Systematic Literature Review. Seattle: PATH; 2003. Cervical Cancer Prevention Issues in Depth, No.1. www.path.org/publications/details.php?i=687
  61. Jacob M, Broekhuizen FF, Castro W, Sellors J. Experience using cryotherapy for treatment of cervical precancerous lesions in low-resource settings. International Journal of Gynaecology and Obstetrics. 2005;89 (Suppl 2):S13–S20.
  62. Denny L, Kuhn L, De Souza M, Pollack A, Dupree W, Wright TJr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. Journal of the American Medical Association. 2005;294(17):2173–2181.
  63. Goldie SJ, Kim JJ, Myers E. Cost-effectiveness of cervical cancer screening. Vaccine. 2006;24:164–170.
  64. Blumenthal PD, Gaffikin L, Deganus S, Lewis R, Emerson M, Adadevoh S. Cervical cancer prevention: safety, acceptability, and feasibility of a single-visit approach in Accra, Ghana. American Journal of Obstetrics and Gynecology. 2007;196(4):407–407.
  65. Schiffman M, Castle PE. The Promise of Global Cervical-Cancer Prevention. New England Journal of Medicine. 2005;353(20):2101–2104.
  66. Sellors J, Lewis K, Kidula N, Muhombe K, Tsu V, Herdman C. Screening and management of precancerous lesions to prevent cervical cancer in low-resource settings. Asian Pacific Journal of Cancer Prevention. 2003;4(3):277–280.
  67. Ngan HYS, Trimble CL. A4. Preinvasive lesions of the cervix. International Journal of Gynecology & Obstetrics. 2006;94(Suppl 1):S44–S49.
  68. ACCP. ACCP Strategies for Supporting Women with Cervical Cancer. Seattle: ACCP; 2004. Cervical Cancer Prevention Issues in Depth, No. 2. Available at:
  69. Pollack AE, Tsu VD. Preventing cervical cancer in low-resource settings: building a case for the possible.International Journal of Gynecology & Obstetrics. 2005;89 (Suppl 2):S1–S3.
  70. WHO, United Nations Population Fund. Preparing for the introduction of HPV vaccines: policy and programme guidance for countries. Geneva: WHO; 2006.
  71. Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M. Education, training, and communication for HPV vaccines. Vaccine. 2006;24:210–218.
  72. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling. Vaccine. 2006;24(Suppl 3):S155–S163.
  73. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24(Suppl. 3):S178–S186.
  74. Batson A, Meheus F, Brooke S. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries. Vaccine. 2006;24 Suppl 3:S219–S225.
  75. Goldie SJ, Kim JJ, Kobus K, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine. 2007;25(33):6257–6270.
  76. Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ. Exploring the cost-effectiveness of HPV vaccination in Vietnam: Insights for evidence-based cervical cancer prevention policy. Vaccine. 2008;26(32):4015–4024.
  77. Diaz M, Kim JJ, Albero G, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. British Journal of Cancer. 2008;99:230–238.
  78. Goldie SJ, O'Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reproductive Health Matters. 2008;16(32):86–96.
  79. de Melo-Martin I. The promise of the human papillomavirus vaccine does not confer immunity against ethical reflection. Oncologist. 2006;11(4):393–396.
  80. Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B. Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine. 2006;24(Suppl. 3):S201–S209.
  81. Blumenthal PD, Lauterbach M, Sellors JW, Sankaranarayanan R. Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy. International Journal of Gynaecology and Obstetrics. 2005;89(Suppl 2):S30–S37.
  82. Jacob M, Bradley J, Barone MA. Human papillomavirus vaccines: what does the future hold for preventing cervical cancer in resource-poor settings through immunization programs? Sexually Transmitted Diseases. 2005;32(10):635–640.
  83. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F. HPV vaccine use in the developing world. Vaccine. 2006;24:132–139.
  84. Bradley J, Barone M, Mahq C, Lewis R, Luciani S. Delivering cervical cancer prevention services in low-resource settings. International Journal of Gynecology & Obstetrics. 2005;89(Suppl 2):S21–S29.
Back Back